Zenas BioPharma, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Zenas BioPharma, Inc. (ZBIO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$38.61 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-11-12
- Zenas BioPharma, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$38.61M, a 1136.96% decline year-over-year.
- Zenas BioPharma, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was $3.72M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|
| 2024-09-30 | -$38.61M 10-Q · filed 2024-11-12 | -$104.38M 10-Q · filed 2024-11-12 |
| 2023-09-30 | $3.72M 10-Q · filed 2024-11-12 | -$12.54M 10-Q · filed 2024-11-12 |